Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications.

Mukherjee N, Wheeler KM, Svatek RS.

Curr Opin Urol. 2019 Feb 11. doi: 10.1097/MOU.0000000000000595. [Epub ahead of print]

PMID:
30762672
2.

What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?

Lerner SP, Svatek RS.

Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31034-0. doi: 10.1016/j.eururo.2018.12.028. [Epub ahead of print] No abstract available.

PMID:
30616946
3.

Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.

Svatek RS, Ji N, de Leon E, Mukherjee NZ, Kabra A, Hurez V, Nicolas M, Michalek JE, Javors M, Wheeler K, Sharp ZD, Livi CB, Shu ZJ, Henkes D, Curiel TJ.

Cancer Immunol Res. 2018 Dec 18. doi: 10.1158/2326-6066.CIR-18-0336. [Epub ahead of print]

PMID:
30563829
4.

Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer.

Mukherjee N, Ji N, Hurez V, Curiel TJ, Montgomery MO, Braun AJ, Nicolas M, Aguilera M, Kaushik D, Liu Q, Ruan J, Kendrick KA, Svatek RS.

Oncotarget. 2018 Nov 23;9(92):36492-36502. doi: 10.18632/oncotarget.26362. eCollection 2018 Nov 23.

5.
6.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.

World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. Review.

PMID:
30109483
7.

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.

Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM.

World J Urol. 2019 Jan;37(1):3-13. doi: 10.1007/s00345-018-2436-y. Epub 2018 Aug 13.

PMID:
30105454
8.

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.

Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM.

Lancet. 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6.

PMID:
29976469
9.

Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration.

Hariharan N, Ashcraft KA, Svatek RS, Livi CB, Wilson D, Kaushik D, Leach RJ, Johnson-Pais TL.

J Obes. 2018 May 20;2018:9247864. doi: 10.1155/2018/9247864. eCollection 2018.

10.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.

JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657.

PMID:
29801011
11.

Editorial Comment.

Svatek RS.

J Urol. 2018 Jun;199(6):1451. doi: 10.1016/j.juro.2017.12.077. Epub 2018 Mar 12. No abstract available.

PMID:
29545192
12.

Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Mukherjee N, Svatek RS, Mansour AM.

Urol Oncol. 2018 Mar;36(3):103-108. doi: 10.1016/j.urolonc.2017.12.020. Epub 2018 Feb 9. Review.

PMID:
29429897
13.

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.

Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, Curiel TJ.

Exp Gerontol. 2018 May;105:146-154. doi: 10.1016/j.exger.2017.12.025. Epub 2018 Jan 8.

PMID:
29326088
14.

Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.

Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, Al Hussein Al Awamlh B, Ouzaid I, Pycha A, Comploj E, Svatek RS, Lotan Y, Karakiewicz PI, Holmang S, Shariat SF.

Urol Oncol. 2018 Mar;36(3):89.e1-89.e5. doi: 10.1016/j.urolonc.2017.11.010. Epub 2017 Dec 6.

PMID:
29221642
15.

Considerations for successful cancer immunotherapy in aged hosts.

Hurez V, Padrón Á, Svatek RS, Curiel TJ.

Exp Gerontol. 2018 Jul 1;107:27-36. doi: 10.1016/j.exger.2017.10.002. Epub 2017 Oct 4. Review.

PMID:
28987644
16.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23.

17.

A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.

Cao W, Tian J, Li C, Gao Y, Liu X, Lu J, Wang Y, Wang Z, Svatek RS, Rodriguez R.

Virol J. 2017 Aug 8;14(1):149. doi: 10.1186/s12985-017-0818-1.

18.

Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M, Kaushik D.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1002-1020. doi: 10.1016/j.ijrobp.2016.11.056. Epub 2016 Dec 13. Review.

PMID:
28332983
19.

Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.

Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS.

J Urol. 2017 Sep;198(3):503-510. doi: 10.1016/j.juro.2017.01.086. Epub 2017 Mar 10. Review.

PMID:
28286068
20.

Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial.

Meeks JJ, Lerner SP, Svatek RS.

J Urol. 2017 Mar;197(3 Pt 1):538-540. doi: 10.1016/j.juro.2016.12.024. Epub 2016 Dec 16. No abstract available.

PMID:
27992750
21.

Considerations for successful cancer immunotherapy in aged hosts.

Hurez V, Padrón ÁS, Svatek RS, Curiel TJ.

Clin Exp Immunol. 2017 Jan;187(1):53-63. doi: 10.1111/cei.12875. Epub 2016 Nov 7. Review.

22.

Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells.

Dao V, Liu Y, Pandeswara S, Svatek RS, Gelfond JA, Liu A, Hurez V, Curiel TJ.

Cancer Res. 2016 Oct 15;76(20):5970-5982. Epub 2016 Aug 28.

23.

Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer.

Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y.

BJU Int. 2016 May;117(5):783-6. doi: 10.1111/bju.13345. Epub 2015 Oct 29.

24.

Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.

Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA.

Eur Urol. 2016 Mar;69(3):407-10. doi: 10.1016/j.eururo.2015.08.029. Epub 2015 Aug 28.

PMID:
26320383
25.

Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9].

Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF.

Eur Urol. 2015 Jul;68(1):171. doi: 10.1016/j.eururo.2015.02.007. Epub 2015 Feb 18. No abstract available.

PMID:
26088736
26.

Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging?

Rozanski AT, Benson CR, McCoy JA, Green C, Grossman HB, Svatek RS, Shah JB.

Bladder Cancer. 2015 Apr 30;1(1):91-96. doi: 10.3233/BLC-150006.

27.

Long-term outcomes of the FinnBladder-4 study.

Svatek RS.

Eur Urol. 2015 Oct;68(4):618-9. doi: 10.1016/j.eururo.2015.04.006. Epub 2015 Apr 15. No abstract available.

PMID:
25890484
28.

Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer.

Boehm BE, Svatek RS.

Urol Clin North Am. 2015 May;42(2):159-68, vii. doi: 10.1016/j.ucl.2015.02.001. Epub 2015 Mar 6. Review.

PMID:
25882558
29.

The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.

Smith ND, Castle EP, Gonzalgo ML, Svatek RS, Weizer AZ, Montgomery JS, Pruthi RS, Woods ME, Tollefson MK, Konety BR, Shabsigh A, Krupski T, Barocas DA, Dash A, Quek ML, Kibel AS, Parekh DJ.

BJU Int. 2015 Feb;115(2):198-205. doi: 10.1111/bju.12699. Review.

30.

Extent of pelvic lymph node dissection during radical cystectomy: is bigger better?

Sundi D, Svatek RS, Nielsen ME, Schoenberg MP, Bivalacqua TJ.

Rev Urol. 2014;16(4):159-66. Review.

31.

Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.

Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, Curiel TJ.

Clin Cancer Res. 2015 Jan 15;21(2):303-11. doi: 10.1158/1078-0432.CCR-14-1781. Epub 2014 Nov 25.

32.

Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population.

Kim SP, Gross CP, Smaldone MC, Han LC, Van Houten H, Lotan Y, Svatek RS, Thompson RH, Karnes RJ, Trinh QD, Kutikov A, Shah ND.

Prostate Cancer Prostatic Dis. 2015 Mar;18(1):13-7. doi: 10.1038/pcan.2014.38. Epub 2014 Oct 14.

PMID:
25311766
33.

Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy.

Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB.

Urology. 2014 Nov;84(5):1147-51. doi: 10.1016/j.urology.2014.05.011. Epub 2014 Aug 28.

PMID:
25174656
34.

Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.

Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y.

Urol Oncol. 2015 Feb;33(2):65.e19-25. doi: 10.1016/j.urolonc.2014.06.009. Epub 2014 Jul 16.

PMID:
25044253
35.

Prospective external validation of a bladder cancer detection model.

Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klatte T, Shariat SF.

J Urol. 2014 Nov;192(5):1343-8. doi: 10.1016/j.juro.2014.05.087. Epub 2014 May 21.

PMID:
24859442
36.

Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.

Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M.

Eur Urol. 2014 Aug;66(2):265-72. doi: 10.1016/j.eururo.2014.02.036. Epub 2014 Feb 26.

PMID:
24630419
37.

Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis.

Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS.

Urology. 2014 Apr;83(4):863-7. doi: 10.1016/j.urology.2013.10.060. Epub 2014 Jan 31.

PMID:
24485993
38.

The economics of bladder cancer: costs and considerations of caring for this disease.

Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, Lotan Y.

Eur Urol. 2014 Aug;66(2):253-62. doi: 10.1016/j.eururo.2014.01.006. Epub 2014 Jan 21. Review.

PMID:
24472711
39.

Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.

Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM.

J Urol. 2014 Jun;191(6):1721-7. doi: 10.1016/j.juro.2013.12.015. Epub 2013 Dec 14.

PMID:
24342144
40.

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.

Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF.

Br J Cancer. 2013 Sep 17;109(6):1460-6. doi: 10.1038/bjc.2013.372. Epub 2013 Aug 27.

41.

Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.

Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB.

Eur Urol. 2013 Jun;63(6):1049-58. doi: 10.1016/j.eururo.2012.12.062. Epub 2013 Jan 8. Review.

PMID:
23313034
42.

Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: a systematic review.

Ramirez JA, McIntosh AG, Strehlow R, Lawrence VA, Parekh DJ, Svatek RS.

Eur Urol. 2013 Oct;64(4):588-97. doi: 10.1016/j.eururo.2012.11.051. Epub 2012 Dec 5. Review.

PMID:
23245816
43.

Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis.

Hilton WM, Lotan Y, Parekh DJ, Basler JW, Svatek RS.

BJU Int. 2013 Jun;111(7):1054-60. doi: 10.1111/j.1464-410X.2012.11499.x. Epub 2012 Nov 21.

44.

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling.

Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF.

Br J Cancer. 2012 Nov 20;107(11):1826-32. doi: 10.1038/bjc.2012.464.

45.

What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up.

Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, Bhat D, Lotan Y.

Urol Oncol. 2014 Feb;32(2):128-34. doi: 10.1016/j.urolonc.2012.07.001. Epub 2012 Nov 13.

PMID:
23153858
46.

Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.

Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF.

Ann Surg Oncol. 2013 Mar;20(3):1027-34. doi: 10.1245/s10434-012-2708-5. Epub 2012 Oct 26.

PMID:
23099729
47.

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.

Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):4-15. doi: 10.1016/j.eururo.2012.09.057. Epub 2012 Oct 4. Review.

PMID:
23083902
48.

Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.

Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, Shariat SF.

Eur Urol. 2013 Nov;64(5):837-45. doi: 10.1016/j.eururo.2012.07.026. Epub 2012 Jul 20.

PMID:
22877503
49.

Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?

Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS.

World J Urol. 2012 Dec;30(6):807-14. doi: 10.1007/s00345-012-0910-5. Epub 2012 Jul 26.

PMID:
22832587
50.

Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.

Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF.

BJU Int. 2013 Jan;111(1):74-84. doi: 10.1111/j.1464-410X.2012.11356.x. Epub 2012 Jul 19.

Supplemental Content

Loading ...
Support Center